{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:47:02Z","timestamp":1770547622060,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ad.2025.104524","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:26:21Z","timestamp":1764865581000},"page":"104524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Postauthorization Safety Study (NISSO) Assessing the Long-Term Safety Profile of Sonidegib in Patients With Locally Advanced Basal Cell Carcinoma: Interim Analysis From the Spanish Cohort"],"prefix":"10.1016","volume":"117","author":[{"given":"S.","family":"Be\u00e0 Ard\u00e9bol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.M.","family":"P\u00e9rez-Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fern\u00e1ndez-de-Misa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Botella-Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ruiz-Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Fl\u00f3rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mayor Arenal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Fuente Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bassas-Freixas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Toll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Valer\u00f3n Almaz\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Arntz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104524_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.ad.2025.104524_bib0170","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ad.2015.12.008","article-title":"Skin cancer incidence and mortality in Spain: a systematic review and meta-analysis","volume":"1074","author":"Tejera-Vaquerizo","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.104524_bib0175","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/ijd.16618","article-title":"Skin cancer mortality in Spain: adjusted mortality rates by province and related risk factors","volume":"62","author":"Alcal\u00e1 Ram\u00edrez Del Puerto","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.104524_bib0180","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13555-020-00382-y","article-title":"Clinical management of locally advanced basal-cell carcinomas and future therapeutic directions","volume":"10","author":"Niebel","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104524_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ijms18112485","article-title":"Understanding the molecular genetics of basal cell carcinoma","volume":"18","author":"Pellegrini","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2025.104524_bib0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.582866","article-title":"Sonidegib for the treatment of advanced basal cell carcinoma","volume":"10","author":"Brancaccio","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ad.2025.104524_bib0195","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind bolt study","volume":"1826","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104524_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2024.100044","article-title":"Interim analysis of the multinational, post-authorisation safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma: time to onset of adverse events","volume":"2","author":"Gutzmer","year":"2024","journal-title":"EJC Skin Cancer"},{"key":"10.1016\/j.ad.2025.104524_bib0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jcm12175631","article-title":"Multicenter retrospective andalusian study of the use of sonidegib for the treatment of local advanced basal cell carcinoma in real clinical practice","volume":"12","author":"Ruiz-Villaverde","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2025.104524_bib0210","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1159\/000530813","article-title":"Real-world experience with vismodegib on advanced and multiple BCCS: data from the relivis study","volume":"2395","author":"Ruiz-Salas","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.104524_bib0215","doi-asserted-by":"crossref","first-page":"T565","DOI":"10.1016\/j.ad.2023.06.011","article-title":"Sonidegib as a locally advanced basal cell carcinoma therapy in real-life clinical setting: a national multicentre study","volume":"114","author":"Moreno-Arrones","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.104524_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113254","article-title":"European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023","volume":"192","author":"Peris","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2025.104524_bib0225","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ad.2025.104524_bib0230","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s13555-021-00588-8","article-title":"Key clinical adverse events in patients with advanced basal cell carcinoma treated with sonidegib or vismodegib: a post hoc analysis","volume":"11","author":"Gutzmer","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104524_bib0235","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of stevie, an international, open-label trial","volume":"86","author":"Basset-S\u00e9guin","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2025.104524_bib0240","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jdv.16230","article-title":"Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion","volume":"34","author":"Dummer","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104524_bib0245","unstructured":"EMA. Summary of product characteristics, odomzo 200mg hard capsules."},{"key":"10.1016\/j.ad.2025.104524_bib0250","unstructured":"EMA. Summary of product characteristics, erivedge 150mg hard capsules."},{"key":"10.1016\/j.ad.2025.104524_bib0255","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"2110","author":"Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2025.104524_bib0260","first-page":"4","article-title":"Immunotherapy and its timing in advanced basal cell carcinoma treatment","volume":"13","author":"Dessinioti","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.ad.2025.104524_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104066","article-title":"Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors","volume":"189","author":"Bossi","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ad.2025.104524_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (vismoneo study): neoadjuvant vismodegib in locally advanced basal cell carcinoma","volume":"35","author":"Bertrand","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ad.2025.104524_bib0275","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/1346-8138.16970","article-title":"Surgery after sonidegib treatment achieves complete response in locally advanced basal cell carcinoma of the face","volume":"51","author":"Paradisi","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2025.104524_bib0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers14102496","article-title":"Eight years of real-life experience with smoothened inhibitors in a Swiss tertiary skin referral center","volume":"14","author":"Grossmann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ad.2025.104524_bib0285","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.18.00794","article-title":"Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter french study of 116 patients","volume":"3734","author":"Herms","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2025.104524_bib0290","doi-asserted-by":"crossref","first-page":"636","DOI":"10.26502\/acmcr.96550535","article-title":"Re-challenge with sonidegib after vismodegib discontinuation in a near-centenarian patient with locally advanced basal cell carcinoma","volume":"6","author":"Di Raimondo","year":"2022","journal-title":"Arch Clin Med Case Rep"},{"key":"10.1016\/j.ad.2025.104524_bib0295","doi-asserted-by":"crossref","first-page":"150","DOI":"10.23736\/S2784-8671.23.07281-X","article-title":"Retreatment with sonidegib in a patient with multiple basal cell carcinomas and multiple comorbidities: a complex real-life scenario","volume":"158","author":"Comito","year":"2023","journal-title":"Ital J Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104524_bib0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dth.15095","article-title":"Sonidegib after vismodegib discontinuation in a patient with gorlin\u2013goltz syndrome and multiple basal cell carcinomas","volume":"34","author":"Piccerillo","year":"2021","journal-title":"Dermatol Therapy"},{"key":"10.1016\/j.ad.2025.104524_bib0305","doi-asserted-by":"crossref","first-page":"2022-3-8","DOI":"10.7573\/dic.2022-3-8","article-title":"Experience with sonidegib in patients with advanced basal cell carcinoma","volume":"11","author":"Puig","year":"2022","journal-title":"Drugs Context"},{"key":"10.1016\/j.ad.2025.104524_bib0310","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1002\/ski2.260","article-title":"Tolerance of sonidegib after intolerance of vismodegib\u2014experience in two patients with nevoid basal cell carcinoma syndrome (gorlin syndrome)","volume":"3","author":"Venturi","year":"2023","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.ad.2025.104524_bib0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/ijms21228596","article-title":"A vismodegib experience in elderly patients with basal cell carcinoma: case reports and review of the literature","volume":"21","author":"Passarelli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2025.104524_bib0320","doi-asserted-by":"crossref","first-page":"76118","DOI":"10.18632\/oncotarget.12660","article-title":"Safety and efficacy of vismodegib in patients aged \u226565 years with advanced basal cell carcinoma","volume":"7","author":"Chang","year":"2016","journal-title":"Oncotarget"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:17:33Z","timestamp":1770470253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025007938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0001731025007938"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104524","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postauthorization Safety Study (NISSO) Assessing the Long-Term Safety Profile of Sonidegib in Patients With Locally Advanced Basal Cell Carcinoma: Interim Analysis From the Spanish Cohort","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104524"}}